Inhaled Alpha 1-Antitrypsin: Gauging Patient Interest in a New Treatment

References

• American Thoracic Society/European Respiratory Society Statement: Standards for the Diagnosis and Management of Individuals with alpha-1-antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168(7):818–900.
   PubMed Web of Science ®Google Scholar
• Kropp J, Wencker M, Hotze A, Inhalation of [123I]alpha1-protease inhibitor: toward a new therapeutic concept of alpha1-protease inhibitor deficiency? J Nucl Med 2001; 42(5):744–751.
   PubMed Web of Science ®Google Scholar
• Meyer T, Müllinger B, Sommerer K, Pulmonary deposition of monodisperse aerosols in patients with chronic obstructive pulmonary disease. Exp Lung Res 2003; 29(7):475–484.
   PubMed Web of Science ®Google Scholar
• Brand P, Schulte M, Wencker M, Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. Eur Respir J 2009; 34(2):354–360.
   PubMed Web of Science ®Google Scholar
• Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung 1990; 168 Suppl:565–578.
   PubMed Web of Science ®Google Scholar
• Siekmeier R. Lung deposition of inhaled alpha-1-proteinase inhibitor (alpha 1-PI) –problems and experience of alpha1-PI inhalation therapy in patients with hereditary alpha1-PI deficiency and cystic fibrosis. Eur J Med Res 2010; 15 Suppl 2:164–174.
   PubMedGoogle Scholar
• International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01217671?term=
nct01217671&rank=1. Accessed August 20, 2012.
   Google Scholar
• Brand P, Beckmann H, Maas-Enriquez M, Peripheral deposition of alpha1-protease inhibitor using commercial inhalation devices. Eur Respir J 2003; 22(2):263–267.
   PubMed Web of Science ®Google Scholar
• Hubbard RC, Casolaro MA, Mitchell M, Fate of aerosolized recombinant DNA-produced alpha 1-antitrypsin: use of the epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance. Proc Natl Acad Sci USA 1989; 86(2):680–684.
   PubMed Web of Science ®Google Scholar
• Smith RM, Traber LD, Traber DL, Spragg RG. Pulmonary deposition and clearance of aerosolized alpha-1-proteinase inhibitor administered to dogs and to sheep. J Clin Invest 1989; 84(4):1145–1154.
   PubMed Web of Science ®Google Scholar
• Hubbard RC, McElvaney NG, Sellers SE, Healy JT, Czerski DB, Crystal RG. Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitryspin deficiency. J Clin Invest 1989; 84(4):1349–1354.
   PubMed Web of Science ®Google Scholar
• Griese M, von Bredow C, Birrer P. Reduced proteolysis of surfactant protein A and changes of the bronchoalveolar lavage fluid proteome by inhaled alpha 1-protease inhibitor in cystic fibrosis. Electrophoresis 2001;22(1):165–171.
   PubMed Web of Science ®Google Scholar
• Cantin AM, Berthiaume Y, Cloutier D, Martel M. Prolastin aerosol therapy and sputum taurine in cystic fibrosis. Clin Invest Med 2006; 29(4):201–207.
   PubMed Web of Science ®Google Scholar
• Hubbard RC, Brantly ML, Sellers SE, Mitchell ME, Crystal RG. Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin. Ann Intern Med 1989; 111(3):206–212.
   PubMed Web of Science ®Google Scholar
• McElvaney NG, Hubbard RC, Birrer P, Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991; 337(8738):392–394.
   PubMed Web of Science ®Google Scholar
• Griese M, Latzin P, Kappler M, alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007; 29(2):240–250.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Kirlath I, Warrington S, Banik N, Ulbrich E, Du Bois RM. The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers. Am J Respir Crit Care Med 1997; 155(2):536–541.
   PubMed Web of Science ®Google Scholar
• Smith RM, Spragg RG, Moser KM. Biologic availability of injected or aerosolized alpha 1 proteinase inhibitor. Prog Clin Biol Res 1987; 236A:203–210.
   PubMedGoogle Scholar
• Cape SP, Villa JA, Huang ET, Yang TH, Carpenter JF, Sievers RE. Preparation of active proteins, vaccines and pharmaceuticals as fine powders using supercritical or near-critical fluids. Pharm Res 2008; 25(9):1967–990.
   PubMed Web of Science ®Google Scholar
• Geller DE, Kesser KC. The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation. J Aerosol Med Pulm Drug Deliv 2010; 23 Suppl 1:S55–S59.
   PubMed Web of Science ®Google Scholar
• Alpha-1 Foundation Research Registry. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00499941?term=nct00499941&rank=1. Accessed August 20, 2012.
   Google Scholar
• Needham M, Stockley RA. Exacerbations in α1-antitrypsin deficiency. Eur Respir J 2005; 25(6):992–1000.
   PubMed Web of Science ®Google Scholar
• The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of α1-antitrypsin. Am J Respir Crit Care Med 1998; 158(1):49–59.
   PubMed Web of Science ®Google Scholar
• Issue summary from Blood Products Advisory Committee 95th Meeting, July 20–21, 2009. http://www.fda.gov/
downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/bloodproductsadvisory
committee/ucm171091.pdf. Accessed July 10, 2012.
   Google Scholar
• Pierce JA. Antitrypsin and emphysema: perspective and prospects. JAMA 1988; 259(19):2890–2895.
   PubMed Web of Science ®Google Scholar